Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the representatives of the nomination committee have been appointed ahead of the annual general meeting 2025. The nomination committee has been appointed in accordance with the principles for the nomination committee which were established by the annual general meeting on April 16, 2024.

According to the principles for the nomination committee that were resolved at the annual general meeting on April 16, 2024, the nomination committee should be appointed as follows. The Company’s largest shareholder, or group of shareholders, as of 30 April 2024, shall have the right to appoint one member of the Nomination Committee. Furthermore, the Nomination Committee shall consist of the chairman of the Board of Directors, who shall also be the convener. In addition, Björn Dahlöf, CSO and Head of Clinical Development in the Company, shall be a member of the Nomination Committee. The Nomination Committee shall thus consist of three persons.

The nomination committee ahead of the annual general meeting 2025 has thus been appointed and comprises:

• Cihan Punar, representing the company’s largest group of shareholders per April 30, 2024
• Joakim Söderström, convening member and Chair of the Board of Cereno
• Björn Dahlöf, CSO and Head of Clinical Development in the Company

One of the members, but not the chairman of the Board of Directors, shall be appointed as chairman of the Nomination Committee. The Nomination Committee’s term of office extends until a new Nomination Committee is appointed.

Shareholders who wish to submit proposals to the nomination committee are welcome to do so via e-mail info@cerenoscientific.com, or to the company’s postal address:

Valberedningen
Cereno Scientific AB
AstraZeneca BioVentureHub
Pepparedsleden 1
431 83 Mölndal

The proposal shall be received by the nomination committee no later than January 31, 2025. The nomination committee’s proposal will be announced in conjunction with the publication of the notice, at the latest.

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. In April 2024, Cereno submitted a Clinical Trial Application (CTA) for a Phase I First-in-Human-Study, expected to start during Q2 2024. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.